Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect
Artivion (NYSE: AORT) will report earnings Thursday after the bell. Last quarter it posted revenue of $116.3M, up 17.5% YoY, but missed analysts’ EPS and slightly missed full-year revenue guidance. This quarter consensus calls for 6.7% YoY revenue growth. Analysts’ estimates were largely unchanged; average price target is $42 vs $27.30.
How this was made
The 30-second read
Why it matters
Traders can use the stated consensus revenue growth (6.7% YoY) and the prior pattern of revenue estimate misses to position for earnings volatility and to focus on whether guidance and EPS trajectory improve.
Market read
This is a pre-earnings expectations setup for AORT, emphasizing prior estimate misses and the upcoming after-hours catalyst.
What to watch
The article emphasizes revenue and EPS misses but does not discuss margins, procedure volumes, or product-specific drivers that often determine post-earnings repricing in medical devices.
Background
The piece frames Artivion’s upcoming earnings against last quarter’s revenue beat, EPS miss, and slightly soft full-year revenue guidance, plus Street reconfirmations.
Ticker impact
Artivion (AORT) is set to report earnings Thursday after the bell, with the article citing recent revenue/EPS misses and current Street expectations.
Expect elevated volatility into the print; direction will likely hinge on whether revenue growth re-accelerates and whether EPS miss narrows versus expectations.
The text provides a clear event timing (after-hours earnings) plus directional context (prior revenue misses, EPS miss last quarter, guidance slightly missing). It does not provide the actual upcoming quarter results, so the magnitude and direction remain uncertain.
Market effects
Healthcare equipment peers are referenced as having reported mixed results, which can influence read-across expectations for Artivion’s quarter.
Limited, primarily US small/mid-cap healthcare equipment sentiment around earnings season.
Low, as the article is company-specific and does not cite global regulatory or macro drivers.
Counterpoint
The stock’s strong run-up into earnings (+10.7% over the last month) could mean expectations are already discounted, so a modest beat or narrower miss could trigger an outsized relief rally.
Key entities
- companyArtivion
NYSE-listed medical device company reporting earnings Thursday after the bell.
- companyMerit Medical Systems
Peer cited as having delivered Q2 revenue growth and a post-results stock move.
- companyPenumbra
Peer cited as having reported Q2 revenues in line with consensus and no stock reaction.
